MARKET

PSTV

PSTV

Plus Therapeutics Inc
NASDAQ
0.6500
-0.0050
-0.76%
After Hours: 0.6590 +0.009 +1.38% 19:59 12/05 EST
OPEN
0.6500
PREV CLOSE
0.6550
HIGH
0.6980
LOW
0.6300
VOLUME
8.64M
TURNOVER
--
52 WEEK HIGH
2.310
52 WEEK LOW
0.1634
MARKET CAP
89.33M
P/E (TTM)
-0.3807
1D
5D
1M
3M
1Y
5Y
1D
Plus Therapeutics presents REYOBIQ data at WFNOS/SNO annual meeting
TipRanks · 2d ago
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
Barchart · 2d ago
Plus Therapeutics Is Maintained at Buy by D. Boral Capital
Dow Jones · 5d ago
Plus Therapeutics Price Target Maintained With a $5.00/Share by D. Boral Capital
Dow Jones · 5d ago
D. Boral Capital Maintains Buy on Plus Therapeutics, Maintains $5 Price Target
Benzinga · 5d ago
Plus Therapeutics To Present ReSPECT Phase 1 Dose Escalation Study Results For Leptomeningeal Metastases At 2025 SABCS
Benzinga · 5d ago
Weekly Report: what happened at PSTV last week (1124-1128)?
Weekly Report · 5d ago
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium
Barchart · 5d ago
More
About PSTV
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.

Webull offers Plus Therapeutics Inc (USA) stock information, including NASDAQ: PSTV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSTV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PSTV stock methods without spending real money on the virtual paper trading platform.